Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Wesley Tong"'
Autor:
Andre Lamy, Wesley Tong, Philip Joseph, Peggy Gao, Mark D. Huffman, Gholamreza Roshandel, Reza Malekzadeh, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Alvaro Avezum, Antonio L. Dans, Habib Gamra, Salim Yusuf
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102651- (2024)
Summary: Background: Cardiovascular disease (CVD) continues to impart a large burden on the global population, especially in lower income countries where affordability limits the use of cardiovascular medicines. A fixed dose combination strategy of a
Externí odkaz:
https://doaj.org/article/9e7d66a0bee844efb88fa88dab4c5c2f
Autor:
Adam Eqbal, Wesley Tong, Andre Lamy, Emilie Belley‐Cote, Domenico Paparella, Alexander Bogachev‐Prokophiev, Alistair G. Royse, Wilko Reents, P. J. Devereaux, Katheryn Brady, Jessica Vincent, Stuart J. Connolly, Richard P. Whitlock
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 10 (2023)
Background The LAAOS III (Left Atrial Appendage Occlusion Study) clinical trial demonstrated that concomitant left atrial appendage (LAA) occlusion leads to a lower risk of ischemic stroke or systemic embolism compared with no occlusion in participan
Externí odkaz:
https://doaj.org/article/71bd0657fd4242bfb2486fdd5386fa03
Autor:
Andre Lamy, Wesley Tong, Philip Joseph, Peggy Gao, Prem Pais, Patricio Lopez-Jaramillo, Marjan Walli-Attaei, Antonio L Dans, Denis Xavier, Shamim Talukder, Anwar Santoso, Habib Gamra, Salim Yusuf
Publikováno v:
European Heart Journal - Quality of Care and Clinical Outcomes. 8:899-908
Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesterol- and multiple blood-pressure-lowering drugs reduces cardiovascular events by 20% compared with placebo in people without cardiovascular disease.
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research.
There is controversy on whether to use incremental monetary net benefit (INMB) or incremental cost-effectiveness ratio (ICER) in health economic evaluations alongside randomized controlled trials. We studied the impact of restricted mean survival tim
Autor:
Andre Lamy, John Eikelboom, Wesley Tong, Fei Yuan, Shrikant I Bangdiwala, Jackie Bosch, Stuart Connolly, Eva Lonn, Gilles R Dagenais, Kelley R H Branch, Wei-Jhih Wang, Deepak L Bhatt, Jeff Probstfield, Georg Ertl, Stefan Störk, P Gabriel Steg, Victor Aboyans, Isabelle Durand-Zaleski, Lars Ryden, Salim Yusuf
Publikováno v:
European heart journal. Quality of careclinical outcomes.
Aims The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial demonstrated that rivaroxaban 2.5 mg BID with aspirin 100 mg was more effective than aspirin 100 mg daily alone for the prevention of cardiovascular (CV) dea
Publikováno v:
International Journal of Technology Assessment in Health Care. 36:317-324
ObjectiveTo investigate the behavior of restricted mean survival time (RMST) and designs of a two-state Markov microsimulation model through a 2 × 4 × 2 full factorial experiment.MethodBy projecting patient-wise 15-year-post-trial survival, we esti
Autor:
Andre Lamy, Wojciech Szczeklik, Jessica Vincent, Sadeesh Srinathan, Emmanuelle Duceppe, Maria Graza Franzosi, Joel L. Parlow, Wesley Tong, Denis Xavier, Rajibul Mian, P. J. Devereaux, Bruce M Biccard, Christian S. Meyhoff
The Management of Myocardial Injury after Non-Cardiac Surgery (MANAGE) trial demonstrated that dabigatran 110 mg twice daily was more effective than placebo in preventing the primary composite outcome of vascular mortality, non-fatal myocardial infar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d58d2ff201853a5d287564db0153e5
https://ruj.uj.edu.pl/xmlui/handle/item/285599
https://ruj.uj.edu.pl/xmlui/handle/item/285599
Autor:
Andre, Lamy, Wesley, Tong, Rajibul, Mian, Jessica, Vincent, Wojciech, Szczeklik, Bruce M, Biccard, Emmanuelle, Duceppe, Maria Graza, Franzosi, Sadeesh K, Srinathan, Christian S, Meyhoff, Joel, Parlow, Denis, Xavier, P J, Devereaux
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 22(1)
The Management of Myocardial Injury after Non-Cardiac Surgery (MANAGE) trial demonstrated that dabigatran 110 mg twice daily was more effective than placebo in preventing the primary composite outcome of vascular mortality, non-fatal myocardial infar
Autor:
Amiram Gafni, Andre Lamy, Eva Lonn, Jackie Bosch, Balakumar Swaminathan, Hyejung Jung, Salim Yusuf, Wesley Tong
Publikováno v:
European heart journal. Quality of careclinical outcomes. 5(3)
Aims The Heart Outcomes Prevention Evaluation-3 (HOPE-3) found that rosuvastatin alone or with candesartan and hydrochlorothiazide (HCT) (in a subgroup with hypertension) significantly lowered cardiovascular events compared with placebo in 12 705 ind
Autor:
Andre Lamy, Amiram Gafni, Wesley Tong, Purnima Rao-Melacini, Kevin R. Bainey, Shamir R. Mehta
Publikováno v:
Canadian Journal of Cardiology. 31:314-319
Background Early invasive intervention is associated with shorter length of stay (LOS) and similar outcomes in a delayed strategy in lower-risk patients with non-ST segment elevation acute coronary syndromes (NSTEACS), but is superior in higher-risk